Show simple item record

dc.contributor.authorKennedy, C
dc.contributor.authorO'Dwyer, V
dc.contributor.authorO'Kelly, S
dc.contributor.authorFarah, N
dc.contributor.authorKennelly, M
dc.contributor.authorTurner, M J
dc.date.accessioned2012-04-25T09:20:04Z
dc.date.available2012-04-25T09:20:04Z
dc.date.issued2012-02
dc.identifier.citationThromboprophylaxis for women undergoing caesarean section. 2012, 105 (2):56-7 Ir Med Jen_GB
dc.identifier.issn0332-3102
dc.identifier.pmid22455243
dc.identifier.urihttp://hdl.handle.net/10147/220494
dc.descriptionThromboprophylaxis for women undergoing caesarean section (CS) was introduced in the hospital in 1995. This study audited the use of tinzaparin prophylaxis in a nested cohort of women who screened negative for diabetes mellitus at 28 weeks gestation. All the women had their weight measured and BMI calculated at the first antenatal visit. Of the 284 women, 68 (24%) had a CS and all received tinzaparin. Of the 68, however, 94% received a dose lower than recommended. Compliance with prophylaxis was complete but compliance with the recommended dosage was suboptimal, which may result in venous thromboembolism after CS despite thromboprophylaxis.en_GB
dc.description.abstractThromboprophylaxis for women undergoing caesarean section (CS) was introduced in the hospital in 1995. This study audited the use of tinzaparin prophylaxis in a nested cohort of women who screened negative for diabetes mellitus at 28 weeks gestation. All the women had their weight measured and BMI calculated at the first antenatal visit. Of the 284 women, 68 (24%) had a CS and all received tinzaparin. Of the 68, however, 94% received a dose lower than recommended. Compliance with prophylaxis was complete but compliance with the recommended dosage was suboptimal, which may result in venous thromboembolism after CS despite thromboprophylaxis.
dc.language.isoenen
dc.rightsArchived with thanks to Irish medical journalen_GB
dc.subject.meshCesarean Section
dc.subject.meshFemale
dc.subject.meshFibrinolytic Agents
dc.subject.meshGuideline Adherence
dc.subject.meshHeparin, Low-Molecular-Weight
dc.subject.meshHumans
dc.subject.meshProspective Studies
dc.subject.meshVenous Thrombosis
dc.titleThromboprophylaxis for women undergoing caesarean section.en_GB
dc.typeArticleen
dc.contributor.departmentUCD Centre for Human Reproduction, Coombe Women and Infant's University Hospital, Cork St, Dublin 8.en_GB
dc.identifier.journalIrish medical journalen_GB
dc.description.provinceLeinsteren
refterms.dateFOA2018-08-22T16:36:20Z
html.description.abstractThromboprophylaxis for women undergoing caesarean section (CS) was introduced in the hospital in 1995. This study audited the use of tinzaparin prophylaxis in a nested cohort of women who screened negative for diabetes mellitus at 28 weeks gestation. All the women had their weight measured and BMI calculated at the first antenatal visit. Of the 284 women, 68 (24%) had a CS and all received tinzaparin. Of the 68, however, 94% received a dose lower than recommended. Compliance with prophylaxis was complete but compliance with the recommended dosage was suboptimal, which may result in venous thromboembolism after CS despite thromboprophylaxis.


Files in this item

Thumbnail
Name:
Article6404.pdf
Size:
9.552Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record